Health China

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2009 Gynecologic Cancer Intergroup proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol,143,69-74
2. 2009 Differential gene expression in primary human skin keratinocytes and fibroblasts in response to ionizing radiation Radiat Res,172,82-95.
3. 2009 Current challenges in clinical management of endometrial cancer Adv Drug Deliv Rev,61,883-889.
4. 2009 Does the Entire Uterus Need to Be Treated in Cancer of the Cervix? Role of Adaptive Brachytherapy. Int J Radiat Oncol Biol Phys.(Epub ahead of print).
5. 2009 Transient dephosphorylation of p53 serine 376 as an early response to ionizing radiation. Radiat Res,171(6),725-34.
6. 2009 Differential gene expression in primary human skin keratinocytes and fibroblasts in response to ionizing radiation. Radiat Res,172(1),82-95.
7. 2009 Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix Am J Clin Oncol,32(4),411-6.
8. 2009 Transient Dephosphorylation of p53 Serine 376 as an Early Response to Ionizing Radiation Radiat Res,171,725-34.
9. 2009 Survival and recurrence in nonmycosis fungoides primary cutaneous lymphoma. Cancer J,15(1),87-92.
10. 2009 Practice Patterns of Radiotherapy in Endometrial Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer,19(3),395-9.
11. 2009 Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study Int J Gynecol Cancer,19(1),163-7.
12. 2009 Patterns of Care for Radiotherapy in Vulvar Cancer: A Gynecologic Cancer Intergroup (GCIG) Study. Int J Gynecol Cancer,19(1),163-7.
13. 2008 Consensus Guidelines for Deliniation of Clinical Target Volume for Intesnsity-=Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer Int J Radiat Oncol Biol Phys,71(2),428-34.
14. 2008 Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial. Int J Radiat Oncol Biol Phys,70(1),111-7.
15. 2008 Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw,6(8),766-94.
16. 2008 The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol,88(2),227-32.
17. 2008 Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol,111(6),1394-402
18. 2008 Changes in gene expression induced by chemoradiation in advanced cervical carcinoma: a microarray study of RTOG C-0128 Gynecol Oncol,109(2),275-9.
19. 2008 Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis Int J Gynecol Cancer,18(2),255-61
20. 2008 Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from RTOG 0128. Clin Cancer Res,15(12),4199-4206.
21. 2007 Gynecologic Cancer Intergroup. Clinical trials in Gynecological Cancer Int J Gynecol Cancer,17(3),547-56.
22. 2007 Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. Cancer,110(9),2092-100.
23. 2007 Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128 Int J Radiat Oncol Biol Phys,69(1),111-7.
24. 2007 An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer Brachytherapy,6(3),201-6.
25. 2007 Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG) Int J Radiat Oncol Biol Phys,68(2),485-90
26. 2007 The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant. Am J Clin Oncol,30(2),156-62.
27. 2007 Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: Results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys,68(4),1081-7.
28. 2007 Clinical trials in gynecological cancer. Int J Gynecol Cancer,17(3),547-56
29. 2007 Cause specific survival following surgery in malignant phyllodes tumor of the female breast. Am J Hematol Oncol,6(5),289-92.
30. 2007 A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys,67(1),104-9.
31. 2006 The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol,29(2),189-95.
32. 2006 Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer,107(10),2392-400.
33. 2006 Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer,107(9),2127-33.
34. 2006 Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: a multi-institutional analysis of 608 women Gynecol Oncol,103(2),661-6.
35. 2006 Ovarian cancer. Clinical practice guidelines in oncology J Natl Compr Canc Netw,4(9),912-39.
36. 2006 Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA,295(4),389-97.
37. 2006 Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer Int J Radiat Oncol Biol Phys,65(5),1411-5
38. 2006 The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer,107(1),108-15.
39. 2006 Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol,24(16),2437-43.
40. 2006 Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res,12(1),250-6.
41. 2005 Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol,99(2),415-21
42. 2005 Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium? Gynecol Oncol,99(3),730-5.
43. 2005 Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128. Gynecol Oncol,97(2),607-11.
44. 2005 Intracranial extramedullary hematopoiesis: brief review of response to radiation therapy Am J Hematol,78(2),151-2.
45. 2004 Time interval to the development of breast carcinoma after treatment for Hodgkin disease Cancer,101(6),1275-82.
46. 2004 Electron arc radiotherapy after breast reconstruction: the results of the University of Utah experience Am J Clin Oncol,27(6),555-564
47. 2004 Ovarian Cancer: Clinical Practice Guidelines J Natl Compr Canc Netw,2(6),526-547.
48. 2004 Is simulation necessary for each high-dose-rate tandem and ovoid insertion in carcinoma of the cervix? Brachytherapy,3(3),120-4
49. 2004 Rapid involution and mobility of carcinoma of the cervix Int J Radiat Oncol Biol Phys,58(2),625-30.
50. 2004 Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy Int J Radiat Oncol Biol Phys,58(4),1034-40.
51. 2004 Does radiotherapy around the time of pregnancy for Hodgkin's disease modify the risk of breast cancer? Int J Radiat Oncol Biol Phys,58(5),1474-9.
52. 2004 Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol,93(1),209-14.
53. 2003 Facilitation of radiotherapeutic error by computerized record and verify systems. Int J Radiat Oncol Biol Phys,56(1),50-7.
54. 2003 Electron arc irradiation of the postmastectomy chest wall in locally recurrent and metastatic breast cancer. Am J Clin Oncol,26(3),241-6.
55. 2003 Diminished survival in patients with inner versus outer quadrant breast cancers. J Clin Oncol,21(3),467-72.
56. 2003 Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys,56(4),922-8
57. 2002 Dose calculation errors due to inaccurate representation of heterogeneity correction obtained from computerized tomography Med Dosim,27(4),275-8.
58. 2002 Long-term follow-up of RTOG 88-05: Twice daily external irradiation with brachytherapy for carcinoma of the cervix Int J Radiat Oncol Biol Phys,54(1),51-7.
59. 2002 Forward planning using multileaf collimation as a replacement for patient tissue compensation. Med Dosim,27(4),245-9
60. 2001 Intensity-modulated radiosurgery/radiotherapy using a micromultileaf collimator. Med Dosim,26(2),143-50.
61. 2001 Gynecology Cancer Working Group Int J Radiat Oncol Biol Phys,51(3 suppl 2),58-9.
62. 2001 Electron arc irradiation of the postmastectomy chest wall with CT treatment planning: 20-year experience. Int J Radiat Oncol Biol Phys,51(4),994-1001.
63. 2001 Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. Am J Clin Oncol,24(5),443-6
64. 2001 Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy Int J Radiat Oncol Biol Phys,49(5),1213-7.
65. 2000 Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations J Clin Oncol,18(19),3360-9.
66. 2000 Comparison of interpolated vs. calculated micromultileaf settings in dynamic conformal arc treatment Med Dosim,25(1),17-21.
67. 2000 Effects of modifying topoisomerase II levels on cellular recovery from radiation damage. Radiat Res,154(4),461-6.
68. 2000 Application of enhanced dynamic wedge to stereotactic radiotherapy Med Dosim,25(2),61-9
69. 1999 Dosimetric comparison between 192-Ir and 125-I for low dose rate interstitial implants of the base of tongue. J Brachyther Int,15(1),27-35.
70. 1999 Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol,30(4),384-91.
71. 1998 Pathobiologic characteristics of hereditary breast cancer. Hum Pathol,29(10),1140-4.
72. 1998 Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol,47(2),129-36
73. 1997 Dose to the contralateral breast: a comparison of two techniques using the enhanced dynamic wedge versus a standard wedge Med Dosim,22(3),185-91.
74. 1997 Electron arc irradiation of the postmastectomy chest wall: clinical results Radiother Oncol,42(1),17-24
75. 1997 Dosimetric parameters of enhanced dynamic wedge for treatment planning and verification. Med Dosim,22(3),177-83
76. 1995 Iododeoxyuridine Radiosensitization of Human Glioblastoma Cells Exposed to Acute and Chronic Gamma Irradiation. Cancer J Sci Am,1(2),151
77. 1992 Merocyanine 540-sensitized photoinactivation of enveloped viruses in blood products: site and mechanism of phototoxicity Blood,80(1),277-85
78. 1992 Antiviral effects of photosensitizing merocyanine dyes: implications for transfusion and bone marrow transplantation Semin Hematol,29(2),79-87
79. 1992 The role of serum and serum components in the merocyanine 540-sensitized photoinactivation of K562 leukemia cells Biochim Biophys Acta,1117(3),321-5.
80. 1992 Merocyanine-sensitized photoinactivation of enveloped viruses Blood Cells,18(1),117-27.
81. 1992 Merocyanine 540-sensitized photoinactivation of enveloped viruses in blood products: site and mechanism of phototoxicity. Blood,80(1),277-85
82. 1992 The role of serum and serum components in the merocyanine 540-sensitized photoinactivation of K562 leukemia cells Biochim Biophys Acta,1117(3),321-5
83. 1991 Cholesterol content but not plasma membrane fluidity influences the susceptibility of L1210 leukemia cells to merocyanine 540-sensitized irradiation. Photochem Photobiol,54(5),717-23.
84. 1991 Plasma membrane properties regulating the sensitivity of leukemia, lymphoma, and solid tumor cells to merocyanine 540-sensitized photoirradiation. Exp Hematol,19(8),785-8.
85. 1991 Modulation by thiols of the merocyanine 540-sensitized photolysis of leukemia cells, red cells, and herpes simplex virus type 1 Photochem Photobiol,53(1),85-92.
86. 1990 Merocyanine 540-sensitized photoinactivation of soluble and membrane-bound enzymes in L1210 leukemia cells. Cancer Res,50(24),7765-9
87. 1990 Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products. J Lab Clin Med,116(4),439-47.
88. 1990 Merocyanine 540-sensitized photoinactivation of leukemia cells: role of oxygen and effects on plasma membrane integrity and mitochondrial respiration. Exp Hematol,18(1),23-6.
89. 1986 Nicotine-induced tolerance and receptor changes in four mouse strains. J Pharmacol Exp Ther,237(3),809-19.
90. 1986 Genetic influences on GABA-related seizures Pharmacol Biochem Behav,24(3),665-72.


Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.